Whitehawk Therapeutics (WHWK) Liabilities and Shareholders Equity (2010 - 2026)

Whitehawk Therapeutics (WHWK) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $127.2 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $127.2 million, down 45.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $625.9 million (up 27.31% YoY), and the FY2025 annual result was $150.8 million, up 114.49% from the prior year.
• Liabilities and Shareholders Equity declined to $127.2 million in Q1 2026 per WHWK's latest filing, from $150.8 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $234.0 million in Q1 2025 and troughed at $70.3 million in Q4 2024.
• A 5-year average of $145.4 million and a median of $142.3 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity jumped 245.76% in 2022, then tumbled 46.9% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $184.2 million in 2022, then decreased by 28.12% to $132.4 million in 2023, then tumbled by 46.9% to $70.3 million in 2024, then surged by 114.49% to $150.8 million in 2025, then dropped by 15.65% to $127.2 million in 2026.
• Business Quant data shows WHWK's Liabilities and Shareholders Equity at $127.2 million in Q1 2026, $150.8 million in Q4 2025, and $167.0 million in Q3 2025.